Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The VDAC2–BAX protein–protein interface is a critical regulatory site for the intrinsic apoptotic pathway, located on the mitochondrial outer membrane (PubMed: 25242322). Voltage-dependent anion-selective channel protein 2 (VDAC2) acts as a mitochondrial anchor for the pro-apoptotic protein BAX (Bcl-2-associated X protein), facilitating its recruitment and subsequent activation (UniProt: P45880). Under normal physiological conditions, VDAC2 is essential for BAX-mediated apoptosis, as its absence significantly impairs BAX translocation and pore formation (PubMed: 31434674). Upon apoptotic signaling, the interaction facilitates BAX oligomerization and mitochondrial outer membrane permeabilization (MOMP), leading to the release of cytochrome c and other pro-apoptotic factors into the cytosol (PubMed: 25242322). In many cancers, the VDAC2–BAX interaction is a focal point for evading apoptosis, making it an attractive target for small-molecule sensitizers. Research has identified small molecules like WEHI-9625 that specifically bind VDAC2 to enhance BAX-mediated killing in certain cancer types, such as melanoma (Nature Chemical Biology: van Delft et al., 2014). Conversely, in neurodegenerative diseases or ischemic injury, inhibiting this interface could potentially preserve cell viability by preventing BAX-induced mitochondrial damage (PubMed: 31434674).
Small molecule modulation of the VDAC2-BAX interaction to either facilitate or inhibit BAX recruitment, oligomerization, and subsequent mitochondrial outer membrane permeabilization (MOMP).
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Voltage-dependent anion-selective channel protein 2–Apoptosis regulator BAX protein–protein interface (VDAC2–BAX interface).